Burstein HJ. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020;383:2557–70. https://doi.org/10.1056/NEJMra1307118.

Article  CAS  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76: 103756. https://doi.org/10.1016/j.breast.2024.103756.

Article  PubMed  PubMed Central  Google Scholar 

Liu C, Ma G, Zhang J, Cheng J, Yang Z, Song S. (18)F-FES and (18)F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment. Ann Nucl Med. 2023;37:675–84. https://doi.org/10.1007/s12149-023-01871-8.

Article  CAS  PubMed  Google Scholar 

Liu C, Hu S, Xu X, Zhang Y, Wang B, Song S, et al. Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment. Breast Cancer Res. 2022;24:57. https://doi.org/10.1186/s13058-022-01555-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boers J, Venema CM, de Vries EFJ, Glaudemans A, Kwee TC, Schuuring E, et al. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer. 2020;126:11–20. https://doi.org/10.1016/j.ejca.2019.10.024.

Article  CAS  PubMed  Google Scholar 

Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O’Connor T, et al. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023;7:90. https://doi.org/10.1038/s41698-023-00438-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res. 2014;16:205. https://doi.org/10.1186/bcr3630.

Article  PubMed  PubMed Central  Google Scholar 

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601–8. https://doi.org/10.1200/jco.2011.37.2482.

Article  PubMed  Google Scholar 

Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21:1254–61. https://doi.org/10.1093/annonc/mdp427.

Article  CAS  PubMed  Google Scholar 

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–9. https://doi.org/10.1200/jco.2005.04.3810.

Article  CAS  PubMed  Google Scholar 

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, et al. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol. 2014;16:431–40. https://doi.org/10.1007/s11307-013-0699-7.

Article  CAS  PubMed  Google Scholar 

Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, et al. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with (18)F-fluoroestradiol ((18)F-FES) CT/PET. Ann Oncol. 2024;35:549–58. https://doi.org/10.1016/j.annonc.2024.02.007.

Article  CAS  PubMed  Google Scholar 

van Geel JJL, Boers J, Elias SG, Glaudemans A, de Vries EFJ, Hospers GAP, et al. Clinical Validity of 16α-[(18)F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. J Clin Oncol. 2022;40:3642–52. https://doi.org/10.1200/jco.22.00400.

Article  PubMed  Google Scholar 

Shin E, Han S, Ryu J, Eom HJ, Choi WJ, Ahn JH, et al. Diagnostic Accuracy of 18F-FES PET/CT for the Detection of Recurrent and Metastatic Breast Cancer. Clin Nucl Med. 2024. https://doi.org/10.1097/rlu.0000000000005447.

Article  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375:1925–36. https://doi.org/10.1056/NEJMoa1607303.

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35:3638–46. https://doi.org/10.1200/jco.2017.75.6155.

Article  CAS  PubMed  Google Scholar 

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15. https://doi.org/10.1016/s1470-2045(18)30292-4.

Article  CAS  PubMed  Google Scholar 

Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646–57. https://doi.org/10.1016/s1470-2045(23)00172-9.

Article  CAS  PubMed  Google Scholar 

Xie Y, Du X, Zhao Y, Gong C, Hu S, You S, et al. Chemotherapy shows a better efficacy than endocrine therapy in metastatic breast cancer patients with a heterogeneous estrogen receptor expression assessed by 18F-FES PET. Cancers. 2022;14:3531.

CAS  PubMed  PubMed Central  Google Scholar 

Parihar AS, Vaz S, Sutcliffe S, Pant N, Schoones JW, Ulaner GA. (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2025;66:692–9. https://doi.org/10.2967/jnumed.124.269163.

Article  PubMed  Google Scholar 

Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, et al. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT. Clin Nucl Med. 2017;42:421–7. https://doi.org/10.1097/rlu.0000000000001587.

Article  PubMed  Google Scholar 

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[(18)F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024;65:221–3. https://doi.org/10.2967/jnumed.123.266938.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026.

Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, et al. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022;150:2025–37. https://doi.org/10.1002/ijc.33959.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8:114. https://doi.org/10.1038/s41523-022-00479-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist. 2023;28:866–74. https://doi.org/10.1093/oncolo/oyad209.

Article  PubMed  PubMed Central